Advertisement
U.S. Markets open in 4 hrs 37 mins

Isofol Medical AB (publ) (ISOFOL.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
3.0050+0.0050 (+0.17%)
As of 10:50AM CET. Market open.

Isofol Medical AB (publ)

Biotech Center
Arvid Wallgrens Backe 20
Gothenburg 413 46
Sweden
46 3 17 97 22 80
https://isofolmedical.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

NameTitlePayExercisedYear Born
Mr. Petter Segelman LindqvistChief Executive OfficerN/AN/AN/A
Ms. Margareta Hagman M.B.A.Chief Financial OfficerN/AN/A1966
Dr. Roger Tell M.D., Ph.D.Chief Medical OfficerN/AN/A1965
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.

Corporate Governance

Isofol Medical AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.